Clinical trials: Early Detection of Ovarian Cancer
Ovarian Cancer
A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus
Ovarian cancer is deadly and generally diagnosed at late stage when the chances of survival are low. There is a current belief that this cancer starts in the fallopian tubes and progresses towards the ovaries, spreading to the…
- Trial name
- NCT01787656
- Where
- United States
- Volunteers
- 438 people
- Sponsor
- University of South Alabama
Ovarian Cancer
A Trial of Fast Access to Transvaginal Ultrasound Through General Practice for Earlier Diagnosis of Ovarian Cancer
Background Ovarian cancer (OC) is a disease with a poor prognosis due to diagnosis at late stage. Early-stage OC presents with non-specific and vague symptoms and therefore OC usually is not detected until reaching an advanced…
- Trial name
- NCT03069872
- Testing
- Transvaginal ultrasound
- Where
- Denmark
- Volunteers
- 490 people
- Sponsor
- University of Aarhus
Ovarian Cancer
Early Detection of Ovarian Cancer Using Plasma Cell-free DNA Fragmentomics (Retrospective Study)
The purpose of this study is to enable non-invasive early detection of ovarian cancer in high-risk populations through the establishment of a multimodal machine learning model using plasma cell-free DNA fragmentomics.
- Trial name
- NCT05693974
- Where
- China
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cancer, Cancer Diagnosis
Avera Cancer Sequencing and Analytics Protocol (ASAP)
The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system.
- Conditions
- Cancer, Cancer Diagnosis, Early Detection of Cancer, Breast Cancer
- Trial name
- ASAP (NCT05142033)
- Where
- 6 sites in United States
- Volunteers
- 25,000 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Ovarian Carcinoma, Ovarian Germ Cell Tumor
Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)
This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers.
- Trial name
- NCT01696994
- Testing
- Laboratory Biomarker Analysis, Screening Questionnaire Administration, Ultrasound Imaging
- Where
- United States
- Volunteers
- 78,216 people
- Sponsor
- National Cancer Institute (NCI)
Gynaecological Cancers, Ovarian Cancer
Methylation Profiling in Self-samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
The goal of the MYSSELF study is to investigate which biological markers (i.e., (epi)genetic biomarkers) found in self-collected samples, such as first-void urine and vaginal samples, are linked to the presence of endometrial…
- Conditions
- Gynaecological Cancers, Ovarian Cancer, Endometrial Cancer, Vulvar Cancer
- Trial name
- MYSSELF (NCT07902375)
- Testing
- Colli-Pee 20 mL device with UCM, Evalyn Brush
- Where
- Belgium
- Volunteers
- 730 people
- Sponsor
- Universiteit Antwerpen
Ovarian Cancer
Screening Women at High Genetic Risk for Ovarian Cancer
RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for ovarian cancer. PURPOSE: Screening trial to determine the best procedure to detect ovarian cancer in women who have a…
- Trial name
- NCT00033488
- Testing
- cytology specimen collection procedure, annual screening, comparison of screening methods
- Where
- 2 sites in United Kingdom
- Volunteers
- 5,000 people
- Sponsor
- University College London Hospitals
Ovarian Cancer Screening Recommendations by Gynecologists
Ovarian Cancer Screening and AI
Gynecologists frequently overestimate the benefits and safety of ovarian cancer screening. AI-supported discussions may help correct these misperceptions.
- Trial name
- AI-OCS-Gyn (NCT07503054)
- Testing
- ChatGPT - Control, ChatGPT - Evidence-Based Screening Discussion
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Charite University, Berlin, Germany
Ovarian Cancer
Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )
This study is a multi-center, observational study aiming at developing a machine learning-based early detection model using prospectively collected liquid biopsy samples from newly diagnosed ovarian cancer.
- Trial name
- NCT06249308
- Testing
- Blood collection
- Where
- 3 sites in China
- Volunteers
- 168 people
- Sponsor
- Fudan University
Ovarian Cancer
Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test
The aim of the project is to corroborate them on a large retrospective cohort of HGS-EOC and confirm the possibility of identify TP53 mutations in high grade endometrioid tumors.
- Trial name
- PAPAudit (NCT04812938)
- Testing
- Patients with Ovarian cancer and pap test available
- Where
- 2 sites in Italy
- Volunteers
- 190 people
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
brca1 Mutation Carrier, brca2 Mutation Carrier
Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer
RATIONALE: Screening tests, such as the lysophosphatidic acid assay, may help doctors find cancer cells early and plan better treatment for ovarian cancer.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
- Trial name
- NCT00986206
- Testing
- Biomarker LPA and HE4
- Where
- United States
- Volunteers
- 525 people
- Sponsor
- Women and Infants Hospital of Rhode Island
Early Detection of Ovarian Cancer
Screening for Ovarian Malignancy
Ovarian cancer is the second most common gynecologic malignancy. In 2008, it was the seventh leading cause of cancer deaths in women worldwide.
- Trial name
- NCT06348784
- Testing
- Assesment of Different NEoplasias in the adenexa model, Risk of malignancy index, Histopathologic examination
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Ain Shams Maternity Hospital
Ovarian Cancer, Ovarian Carcinoma
Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage
Screening programs for high-grade ovarian carcinoma failed to reduce disease-specific mortality, since they do not offer early enough detection of the disease.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- BEDOCA (NCT03150121)
- Testing
- Uterine lavage, Blood sample, Uterine lavage catheter
- Where
- 4 sites in Israel
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Breast Neoplasms, Uterine Cervical Neoplasms
Early Detection of Cancers in Low Resource Countries
The purpose of this study is to implement a community-based combined program for early detection of breast, cervical, ovarian and endometrial cancer in low-resource countries delivered through a free standing or a mobile Well…
- Conditions
- Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms
- Trial name
- NCT01178736
- Testing
- Breast Cancer Screening and Diagnosis, Cervical Cancer Screening and Diagnosis, Ovarian Cancer Screening and Diagnosis
- Where
- 3 sites in Brazil, Cambodia and 1 more
- Volunteers
- 36,000 people, healthy volunteers welcome
- Sponsor
- Woman's Cancer Foundation
Ovarian Cancer
CA-125 in Screening Patients at High Risk for Ovarian Cancer
RATIONALE: Measuring levels of CA 125 in blood samples of women who have a high risk of developing ovarian cancer may help doctors detect cancer early and plan more effective treatment.
- Trial name
- NCT00080639
- Testing
- physiologic testing, study of high risk factors
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
High Grade Serous Ovarian Cancer, Cervical Cancer Screening
Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer
High-grade serous ovarian carcinoma (HGSOC) is the deadliest gynaecological tumour. The 5-year overall survival rate for advanced-stage disease is less than 30 per cent, due to diagnosis at an advanced stage.
- Conditions
- High Grade Serous Ovarian Cancer, Cervical Cancer Screening, Whole Genome Sequencing, Genomic Instability
- Trial name
- SHALLOW ROUTE (NCT07821879)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut Claudius Regaud
Ovarian Cancer
Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer
RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for ovarian cancer. PURPOSE: Screening trial to determine the significance of cancer antigen 125 (CA125) levels in detecting…
- Trial name
- NCT00039559
- Testing
- Early detection
- Where
- United States
- Volunteers
- 2,430 people
- Sponsor
- Massachusetts General Hospital